SGLT2 Inhibitors Versus Metformin as First-Line Therapy for Cardiorenal Outcomes: A Target Trial Emulation Among New Users With Type 2 Diabetes

Mayo Clinic Proceedings · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles